SUNNYVALE, Calif., July 11 /PRNewswire-FirstCall/ --
Scios Inc. (Nasdaq: SCIO) today announced that Suzanne Beveridge has been
appointed senior director, investor relations and corporate communications.
Ms. Beveridge will report to David Gryska, senior vice president and chief
financial officer, and lead investor and public relations and media
communications.
Ms. Beveridge joins Scios from Amgen where she was most recently associate
director, investor relations, serving as a key communicator to the financial
community for the past three years. She joined Amgen in Australia in 1992 and
held positions in sales and marketing before transferring to Amgen
headquarters in California for an international business development position.
"Suzanne's extensive experience in high-growth biotechnology business and
investor communications is a valuable asset to Scios as we build on the
success of Natrecor(R) and advance our new product pipeline to become a
top-tier biopharmaceutical company," said Richard B. Brewer, president and
chief executive officer of Scios.
Ms. Beveridge holds a Masters of Business from the University of
Technology in Sydney, Australia and a Bachelor of Applied Science from the
Queensland University of Technology, Australia.
Scios Inc.
Scios is a biopharmaceutical company that discovered, developed and
markets Natrecor(R) (nesiritide), the first new treatment for acutely
decompensated congestive heart failure in more than a decade. Scios has a
growing pipeline, including SCIO-469, one of the first oral p38 kinase
inhibitors in clinical trials. The Company's disease-based technology
platform integrates expertise in protein biology with computational and
medicinal chemistry to identify novel targets and rationally design small
molecule compounds for large markets with unmet medical needs.
Forward Looking Safe Harbor Disclaimer
This news release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. We generally identify such forward-looking statements
using words like "believe," "intend," "expect," "may," "should," "plan,"
"project," "contemplate," "anticipate" or similar statements. Statements that
are not historical facts are forward-looking statements based on current
assumptions that involve risks and uncertainties. These risks and
uncertainties may include the sales penetration and success of Natrecor, the
success of clinical trials of Natrecor and our pipeline products, including
SCIO-469, as well as other risks detailed from time to time in the reports
filed by Scios with the SEC, including the Company's quarterly reports and
annual report on Form 10-K. Actual results, performance or achievements of
Scios may differ significantly from those described in these forward-looking
statements. Scios disclaims any intention or obligation to update or revise
any financial projections or forward-looking statements, whether as a result
of new information, future events or otherwise.
SOURCE Scios, Inc.
 back to top
Related links:
http://www.sciosinc.com
CONTACT:
Media & Investors, Suzanne Beveridge of
Scios, Inc., +1-408-616-2947; or Media, Jim Weiss of WeissCom
Partners, +1-415-260-1274, or Investors, Fern Lazar of Lazar
Partners, +1-212-867-1765, both for Scios, Inc.
|
